Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study.

MLA

Peng, Zi-Yang, et al. “Chronic Kidney Outcomes Associated with GLP-1 Receptor Agonists versus Long-Acting Insulins among Type 2 Diabetes Patients Requiring Intensive Glycemic Control: A Nationwide Cohort Study.” Cardiovascular Diabetology, vol. 22, no. 1, Oct. 2023, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s12933-023-01991-5.

APA

Peng, Z.-Y., Yang, C.-T., Lin, W.-H., Yao, W.-Y., Ou, H.-T., & Kuo, S. (2023). Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study. Cardiovascular Diabetology, 22(1), 1–12. https://doi.org/10.1186/s12933-023-01991-5

Chicago

Peng, Zi-Yang, Chun-Ting Yang, Wei-Hung Lin, Wen-Yu Yao, Huang-Tz Ou, and Shihchen Kuo. 2023. “Chronic Kidney Outcomes Associated with GLP-1 Receptor Agonists versus Long-Acting Insulins among Type 2 Diabetes Patients Requiring Intensive Glycemic Control: A Nationwide Cohort Study.” Cardiovascular Diabetology 22 (1): 1–12. doi:10.1186/s12933-023-01991-5.